Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15274)	2/18/1998 11:41:00 PM
From: Flagrante Delictu	Respond to of 32384

Henry, RE: a buyout of LGND. Since the LGND management left big pharma to find fame & fortune at LGND, it would not seem likely that they would willingly sell out to big pharma without substantial inducements. A number of big pharmas seem to have concluded that collaborations with bios are preferable to takeovers. This way the bio maintains its' ability to produce in its' own culture, & to derive great rewards if greatly productive. Big pharma makes plenty on the deal, unless their lawyers get outwitted by the bio's. Each party can win big without too much of the friction that could arise from a culture clash in a merger. And LGND management & staff keep their jobs & perks. Bernie.